The incidence of cancer is increased in patients with diabetes mellitus. Numerous
epidemiological studies confirm this phenomenon, specifically with malignancies of the pancreas,
liver, bile ducts, uterus, kidney, breast in postmenopausal women, colon, bladder and aggressive
forms of prostate cancer. Disruption of homeostatic glucose metabolism may play a significant role in
malignant cellular transformation and disease progression. Additionally, recent advances in molecular and biochemical
technology allow for deeper understanding of the pathophysiology of disrupted glucose-insulin axis pathways in diabetics
at the subcellular level. These technological advances may provide answers as to how malignant cellular transformation
occurs and identify potential treatment targets.